Latest

3 stories

Hide weekly roundups

Thursday, August 6

BioLife Solutions posts Q2 2026 results as Repligen acquisition heads toward Q4 close

BioLife reported 21% revenue growth and a GAAP net income boosted by a tax benefit while confirming its pending sale to Repligen is expected to close in the fourth quarter of 2026.

SEC filing

Monday, August 3

PeopleBiolife Solutions INC

BioLife shares employee video from Repligen CEO on pending merger

BioLife Solutions filed an 8-K on August 3, 2026 disclosing a video message from Repligen's CEO to BioLife employees about the companies' planned merger.

SEC filing

Wednesday, July 22

M&ABiolife Solutions INC

Repligen to acquire BioLife Solutions for about $1.5 billion

The deal pays BioLife holders cash and stock worth $31.00 per share and is expected to close in the fourth quarter of 2026.

SEC filing